One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation | Zendy

Tomohiro Tanaka | Zendy; Eberhard L. Renner | Zendy; Nazia Selzner | Zendy; George Therapondos | Zendy; Leslie Lilly | Zendy

Open Access

One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation

Author(s) -

Tomohiro Tanaka,

Eberhard L. Renner,

Nazia Selzner,

George Therapondos,

Leslie Lilly

Publication year - 2014

Publication title -

canadian journal of gastroenterology and hepatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.921

H-Index - 65

eISSN - 2291-2797

pISSN - 2291-2789

DOI - 10.1155/2014/839014

Subject(s) - medicine , lamivudine , liver transplantation , hepatitis b virus , hepatitis b , adverse effect , gastroenterology , liver function , liver disease , transplantation , prospective cohort study , immunology , virus

Hepatitis B immunoglobulin (HBIG) given in combination with a nucleos(t)ide analogue has reduced the rate of recurrent hepatitis B virus (HBV) infection following liver transplantation (LT); however, the most effective protocol remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research